Publications by authors named "Daniel Holyoake"

Claim this Profile
S
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial.
Somnath Mukherjee, Cathy Qi, Rachel Shaw, Christopher M Jones, John A Bridgewater, Daniel Holyoake

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoradiotherapy or Surgery for Very Early Esophageal Squamous Cancer: Can a Nonrandomized Trial Give Us the Answer?
Daniel L P Holyoake, Elizabeth C Smyth

Gastroenterology· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic".
Christopher M Jones, Ganesh Radhakrishna, Katharine Aitken, John Bridgewater, Pippa Corrie, Daniel Holyoake

Br J Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer.
Daniel L P Holyoake, Maxwell Robinson, Michael Silva, Derek Grose, David McIntosh

Radiother Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre- and postoperative prognostic factors for resectable esophageal adenocarcinoma.
Pedro Serralheiro, Adeline Rankin, Allan Clark, Daniel Holyoake, Edward Cheong

Surg Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy.
Sean M O'Cathail, Thomas Smith, Rob Owens, Anthi Zeniou, Yatman Tsang, Daniel L P Holyoake

Radiother Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position.
Christopher M Jones, Ganesh Radhakrishna, Katharine Aitken, John Bridgewater, Pippa Corrie, Daniel Holyoake

Br J Cancer· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic review and meta-analysis of small bowel dose-volume and acute toxicity in conventionally-fractionated rectal cancer radiotherapy.
Daniel L P Holyoake, Mike Partridge, Maria A Hawkins

Radiother Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data.
Daniel L P Holyoake, Marianne Aznar, Somnath Mukherjee, Mike Partridge, Maria A Hawkins

Radiother Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer.
Daniel L P Holyoake, Maxwell Robinson, Derek Grose, David McIntosh, David Sebag-Montefiore

Radiother Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.
Daniel L P Holyoake, Elizabeth Ward, Derek Grose, David McIntosh, David Sebag-Montefiore

BMC Cancer· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The virtual bronchoscopy simulator - a young physician's view.
Daniel Holyoake

Clin Med (Lond)· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis